Table 3.

Odds of ≥2 SOREMS on MSLT in patients who discontinued REMS-AD prior to MSLT.

	Unadjusted Model		Model 1		Model 2		Model 3
	Not Using a REMS-AD	Using a REMS-AD During MSLT	Not Using a REMS-AD	Using a REMS-AD During MSLT	Not Using a REMS-AD	Using a REMS-AD During MSLT	Not Using a REMS-AD	Using a REMS-AD During MSLT
REMS-AD discontinued prior to MSLT	2.21 (1.23–3.98)	12.20 (1.60–92.94)	2.45 (1.32–4.52)	12.08 (1.57–92.46)	3.33 (1.69–6.56)	10.75 (1.39–83.14)	3.16 (1.49–6.68)	8.11 (1.01–65.27)

Values are ORs (95% CIs). Model 1 adjusted for age, sex and BMI; model 2 additionally adjusted for depression, shift work, and benzodiazepine, nBBRA, and non–REM-suppressant antidepressant use; model 3 additionally adjusted for total sleep time on actigraphy and total sleep time and arousal index on PSG. BMI = body mass index; CI = confidence interval; MSLT = multiple sleep latency testing; nBBRA = nBBRA, non–benzodiazepine benzodiazepine receptor agonist; OR = odds ratio; PSG, polysomnography; SOREM = sleep-onset rapid eye movement episode; REM rapid eye movement; REMS-AD = rapid eye movement–suppressing antidepressant.